The DOI matches its Crossref record.
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Abstract
PURPOSE: Paclitaxel has shown significant activity in advanced ovarian cancer. In vitro studies with paclitaxel have suggested that fractionated brief infusion schedules may be more effective than the standard 24-hour infusion. We commenced a phase I evaluation of escalating-dose paclitaxel (40, 50, 60, 80, 100 mg/m2) administered weekly as a 1-hour infusion in patients with recurrent ovarian cancer. All patients had received prior paclitaxel and cisplatin therapy. All patients received standard premedication. PATIENTS AND METHODS: Eighteen patients are assessable on this phase I study. The mean age was 54 years (range, 48 to 74). The median number of prior chemotherapy regimens was three (range, two to five). The mean paclitaxel-free interval was 10.1 months (range, 1 to 24). RESULTS: A total of 194 cycles of therapy were administered, with a mean of 10 (range, one to 12) per patient. No mucositis or grade III neuropathy was seen. Alopecia occurred in one out of 18 assessable patients. The mean neutrophil nadir was 4.0 x 10(9)/L. At the top dose level (100 mg/m2) delivered, dose-intensity was 90.75% of that planned and greater than two fold the standard dose-intensity. Partial responses were seen in four of 13 assessable patients (30%). Two patients with progression of disease on standard three-week paclitaxel schedules switched to a weekly schedule with demonstrated response. Increasing paclitaxel dose correlated with measured area under the curve (AUC) (R2 = .614). Dose-limiting toxicity was reached at 100 mg/m2 with two of three patients experiencing a treatment delay, thus defining a maximum-tolerated dose of 80 mg/m2 in this group of heavily pretreated patients on this weekly schedule. CONCLUSION: (1) Paclitaxel administered as a 1-hour infusion is well tolerated; (2) this schedule of administration does not result in cumulative myelosuppression; and (3) this schedule of administration results in dose-intensive paclitaxel delivery with a favorable toxicity profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Socinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
Second-Line Treatment of Ovarian Cancer
Markman, M., & Bookman, M. A. (2000) · The Oncologist · doi:10.1634/theoncologist.5-1-26 · Cited by 296
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.937 · Cited by 269
Metadata
- Authors
- Fennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L., & Spriggs, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-01
- Volume
- 15
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1839380746
- Cited by
- 242
- References
- 0
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. https://app.cochat.ai/papers/10.1200/jco.1997.15.1.187
- The paper
- Fennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L., & Spriggs, D. (1997). Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1997.15.1.187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.